Methodology & Data Integrity Framework
A scientific, transparent breakdown of how CBPM Registry aggregates multi-pharmacy stock telemetry, calculates clinic running costs, verifies laboratory analyses, and enforces data consensus.
Data Architecture & Ingestion Pipeline
The UK medical cannabis supply chain consists of over a dozen licensed dispensing pharmacies, multiple pharmaceutical importers, and international licensed producers operating across Canada, Australia, Denmark, Germany, Portugal, and North Macedonia.
CBPM Registry deploys a multi-tiered ingestion engine that unifies disparate inventory feeds into a singular, normalized data schema. Background workers process formulary deltas every 2 hours, performing cryptographic checksum comparisons to detect stock transitions, price revisions, and batch updates without latency.
The 5 Standardized Stock Telemetry States
To eliminate ambiguous terms like "available on order" or "limited quantity", CBPM Registry normalizes all dispensary telemetry into a finite state machine:
Verified physical inventory held at dispensing pharmacy vaults. Prescription orders can be fulfilled and dispatched within standard 24–48hr pharmacy turnaround times.
Dispensary inventory has dropped below critical buffer thresholds. Batches are nearing exhaustion; prescribers are cautioned to confirm allocation prior to script rewriting.
Inventory depleted across central distribution vaults. Prescriptions issued for this cultivar will result in rewrite delays or pharmacy rewrites to clinical alternatives.
Import permit issued, Home Office customs clearance pending, or batch currently undergoing mandatory UK secondary laboratory microbial and potency release testing.
Product permanently delisted by the licensed producer, discontinued due to cultivar retirement, or failed regulatory re-authorisation. Retained in historical formulary for retrospective patient records.
Quorum Consensus Scoring Algorithm
In addition to automated pharmacy feeds, CBPM Registry integrates crowdsourced telemetry from verified UK patients. To guard against malicious false reports, spoofed inventory runs, or accidental misinformation, we implement a weighted quorum scoring system:
Formulary Standardization & Pharmacological Taxonomy
All botanical cultivars and processed extracts are catalogued using standardized pharmaceutical criteria rather than subjective commercial marketing claims:
- • Type 1 (THC-Dominant): High Δ9-THC (>15%), low CBD (<1%). Primary indication for intractable pain, nausea, and spasticity.
- • Type 2 (Balanced): Moderate THC (5–12%) and CBD (5–12%) in approximately 1:1 or 1:2 ratios. Reduces psychotropic incidence.
- • Type 3 (CBD-Dominant): High CBD (>10%), trace THC (<1%). Indicated for inflammatory disorders and seizure management.
- • Non-Irradiated: Cultivated in strict GMP aseptic cleanrooms; validated microbial counts comply with European Pharmacopoeia (Ph. Eur.) Chapter 5.1.8.
- • Beta Electron-Beam (E-Beam): High-velocity electron sterilization penetrating flower tissue without radioactive isotopes.
- • Gamma Irradiation: Cobalt-60 isotope sterilization ensuring zero viable microbial spores; suitable for immunosuppressed patients.
Clinic First-Year Cost Calculation Standard
Clinic pricing in the UK is frequently distorted by low initial headline consultation fees offset by recurring repeat charges or compulsory monthly membership subscriptions. To provide equitable comparison, CBPM Registry standardizes 1st-year costs using the following mathematical model:
Where a clinic operates an inclusive subscription model (e.g., all follow-ups and repeats covered in a fixed monthly or annual fee), the formula evaluates the exact 12-month net expenditure including onboarding and transfer fees.
Certificate of Analysis (COA) Verification Protocol
Certificates of Analysis published in our repository undergo strict validation prior to ingestion: